Furthermore, the PFS benefit obtained with lorlatinib, exceeding 5 years, is the longest PFS that has ever been reported with a single-agent targeted treatment in ALK + NSCLC.39 This evidence concerns the gene ALK and non-small cell lung carcinoma.